Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Receptos provides update on progress of lead product candidate RPC1063
Improved self-efficacy in persons with relapsing remitting multiple sclerosis after an intensive social cognitive wellness program with participation of support partners: a 6-months observational study.
Safety and Efficacy of Orally Administered Laquinimod Versus Placebo for Treatment of Relapsing Remitting Multiple Sclerosis (RRMS) (ALLEGRO)
Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients.
FDA warns about seizures linked to MS drug
Systematic review: Efficacy and safety of medical marijuana in selected neurologic disorders: Report of the Guideline Development Subcommittee of the American Academy of Neurology.
Study Suggests Targeting B Cells May Help with MS
Normal outcome of pregnancy with ongoing treatment with natalizumab.
Early bilateral cystoid macular oedema secondary to fingolimod in multiple sclerosis.
Effects of Panax ginseng in Neurodegenerative Diseases.
Acorda Therapeutics announces positive AMPYRA® (dalfampridine) Phase 2 data in people with post-stroke deficits
[Diagnosis of multiple sclerosis - the 2010 revision of the McDonald criteria.]
Medical marijuana: clearing away the smoke.
Receptos begins enrollment of Phase 3 trial of RPC1063 in relapsing multiple sclerosis
Comprehending the inexplicable: qualitative accounts of black Caribbean and white british people severely affected by multiple sclerosis.
Differentiating neuromyelitis optica from other causes of longitudinally extensive transverse myelitis on spinal magnetic resonance imaging.
Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational study.
Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis.
Physiopathology of symptoms and signs in multiple sclerosis.
Summary of evidence-based guideline: Complementary and alternative medicine in multiple sclerosis: Report of the Guideline Development Subcommittee of the American Academy of Neurology.
Long-term adherence of patients with relapsing-remitting multiple sclerosis to subcutaneous self-injections of interferon β-1a using an electronic device: the RIVER study.
Drugs to be Discontinued
The clinically-tested S1P receptor agonists, FTY720 and BAF312, demonstrate subtype-specific bradycardia (S1P₁) and hypertension (S1P₃) in rat.
3D models of human ERα and ERβ complexed with coumestrol.
Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives.

Pages